How to Order Prescriptions

---

Description

ENTYCE® (capromorelin oral solution) is indicated for appetite stimulation in dogs. See package insert for complete product details.

ENTYCE® (capromorelin oral solution) is a selective ghrelin receptor agonist that binds to receptors and affects signaling in the hypothalamus to cause appetite stimulation and binds to the growth hormone secretagogue receptor in the pituitary gland to increase growth hormone secretion. 

ENTYCE® (capromorelin oral solution) is indicated for appetite stimulation in dogs. ENTYCE® for dogs is supplied as a 30-mg/mL flavored oral solution for ease of administration.

ENTYCE® (capromorelin oral solution), the only FDA-approved therapeutic designed to safely and effectively stimulate appetite in dogs. ENTYCE® works by mimicking ghrelin (the “hunger hormone”). Administered orally once a day, ENTYCE® is appropriate to treat inappetence caused by chronic and acute conditions.

Take control of appetite

• ENTYCE® (capromorelin oral solution) is the ONLY FDA-approved therapeutic that was developed specifically to stimulate appetite in dogs
• ENTYCE®has a targeted mechanism of action that mimics ghrelin (the “hunger hormone”) to trigger the feeling of hunger
• ENTYCE®is proven to effectively and safely stimulate appetite in dogs
• ENTYCE®treats the symptom of inappetence so that you can diagnose the underlying chronic or acute condition

Convenient, once-daily oral solution for treating inappetence

ENTYCE® is a selective ghrelin receptor agonist that binds to receptors that stimulate appetite. A laboratory study conducted with ENTYCE® showed an increased appetite in normal healthy dogs. In a clinical trial, ENTYCE® was proven effective in dogs with a reduced or no appetite due to various underlying medical conditions. Good appetite and nutrition help support overall health and are important factors a veterinarian considers when managing disease conditions in dogs. The side effects of ENTYCE® include diarrhea, vomiting, increased thirst, and increased salivation. The drug should be used with caution in dogs with liver or kidney problems. ENTYCE® must be prescribed by a licensed veterinarian because professional expertise is needed to diagnose and manage decreased appetite in dogs and to monitor patients for possible adverse effects of the drug.

ENTYCE® (capromorelin oral solution) is a ghrelin receptor agonist that mimics the effect of ghrelin (the “hunger hormone”). Like naturally occurring ghrelin, ENTYCE® binds to specific cell receptors and affects signaling in the hypothalamus, causing the feeling of hunger.

Dosage and Administration

Administer ENTYCE® orally at a dose of 3 mg/kg (1.4 mg/lb) body weight once daily. To administer ENTYCE®, gently shake the bottle, and then withdraw the appropriate amount of solution using the provided syringe. Rinse syringe between treatment doses. The effectiveness of ENTYCE® has not been evaluated beyond 4 days of treatment in the clinical field study (See Effectiveness).
 

Recommended Dose

• 3 mg/kg (1.4 mg/lb) body weight once daily
• 3 mg/kg = 0.1 mL/kg

by Aratana